Cerus/Baxter suffer red blood cell-cleaning tech setback
This article was originally published in Clinica
Executive Summary
Shares in Cerus plunged yesterday after the firm and developmental partner Baxter International announced they were halting phase III trials of their pathogen inactivation system for red blood cells.